Article
Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.
Molecular cancer therapeutics - 1 Feb 2015
Meador Catherine B, Jin Hailing, de Stanchina Elisa, Nebhan Caroline A, Pirazzoli Valentina, Wang Lu, Lu Pengcheng, Vuong Huy, Hutchinson Katherine E, Jia Peilin, Chen Xi, Eisenberg Rosana, Ladanyi Marc, Politi Katerina, Zhao Zhongming, Lovly Christine M, Cross Darren A E, Pao William
Abstract excerpt
Metastatic EGFR-mutant lung cancers are sensitive to the first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib, and afatinib, but resistance develops. Acquired resistance to gefitinib or erlotinib occurs most commonly (>50%) via the emergence of a second-site EGFR mutation, T790M. Two strategies to overcome T790M-mediated resistance are dual inhibition of EGFR with afatinib plus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.